Rasmussen encephalitis tissue transfer program

Rasmussen encephalitis (RE) was first described in 1958 by Theodore Rasmussen and colleagues at the Montreal Neurological Institute. RE is a very rare neuro-inflammatory disease characterized by intractable seizures and progressive unilateral neurologic deficits. For most diagnosed cases, resection or disconnection of the affected cerebral hemisphere is the only effective treatment. The extreme rarity of the disease has hampered efforts to understand the cause of RE and to develop alternative nonsurgical treatments. Usually only one or two RE cases may been seen annually at a pediatric epilepsy surgery center, thus it may take many years to accrue enough surgical specimens for research studies, especially those involving modern molecular techniques. In 2011, The RE Children's Project (www.REChildrens.org), a nonprofit organization founded to increase awareness of the disease and support research focused on finding a cure, brought together investigators from around the world to launch the RE Children's Research Consortium and discuss ways to accelerate the pace of RE research. With the support of the RE Children's Project, researchers at Johns Hopkins School of Medicine and David Geffen School of Medicine at UCLA launched an international Tissue Transfer Program and data bank to speed up the pace of RE research. The goal of the Tissue Transfer Program is to collect RE surgical specimens from epilepsy centers around the world and to make biologic samples and clinical data available for RE research. Between 2011 and 2012, the program was initiated with coordination managed at Johns Hopkins and in 2013 the role was transferred to UCLA. A central repository for the collected samples was established within the Rare Epilepsies and Brain Disease Tissue Bank in the Department of Neurosurgery at UCLA (http://neurosurgery.ucla.edu/rare-epilepsies-tissue-bank). Excess material from a planned epilepsy surgery that would otherwise be discarded, per institutional guidelines, would be collected for this purpose. All logistics would be handled by the Rare Epilepsies and Brain Disease Tissue Bank Coordinator at UCLA, who would liaise with donor institutions to facilitate the transfer of surgical specimens at no cost to the participating institution. Institutional review board (IRB) approval was obtained to collect surgical specimens from outside institutions, and to distribute material to other centers with institutionally approved research studies. Since the inception of the Tissue Transfer Program, RE specimens have been collected from 33 surgeries at 19 epilepsy centers in six countries (Fig. 1). Stored specimens include both fixed and frozen brain tissue, cerebrospinal fluid, whole blood, plasma, purified peripheral blood mononuclear cells, and brain-infiltrating lymphocytes. With increased awareness of this program, we hope that the pace of RE research will be accelerated. Epilepsy surgery centers around the world are invited to contribute samples and participate in this international effort to cure RE. Applications to access the RE repository should be directed to the Rare Epilepsies and Brain Disease Tissue Bank Coordinator at UCLA (http://neurosurgery.ucla.edu/rare-epilepsies-tissue-bank-contact-us). The Scientific Advisory Board of the RE Children's Project will review applications for research studies to ensure a fair and rigorous assessment of the proposed work. In addition to RE, the Rare Epilepsies and Brain Disease Tissue bank is actively collecting specimens from other rare or uncommon pediatric epilepsy surgery cases including hemimegalencephaly (HME), focal cortical dysplasia (FCD), and tuberous sclerosis (TSC). For more information visit http://neurosurgery.ucla.edu/rare-epilepsies-tissue-bank. We are very grateful to the families who participated in this work. This initiative was made possible by the support of the RE Children's Project; Seth Wohlberg, CFA, CAIA, Founder; Scientific Advisory Board: Christian G. Bien, Epilepsy Center Bethel, Bielefeld, Germany; Chris Cotsapas, Departments of Neurology and Genetics, Yale School of Medicine, New Haven, CT, U.S.A.; Program in Medical and Population Genetics and Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, U.S.A.; J. Helen Cross, The Prince of Wales's Chair of Childhood Epilepsy, UCL-Institute of Child Health, Great Ormond Street Hospital for Children, London, United Kingdom; Frances E. Jensen, Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, U.S.A.; Carlos A. Pardo, Departments of Neurology and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.; Gary W. Mathern, Department of Neurosurgery, UCLA Pediatric Epilepsy Surgery Program and Neurobiology of Epilepsy Research Laboratory, David Geffen School of Medicine at UCLA, Los Angeles, CA, U.S.A. Gary Mathern serves on the Editorial Board and International League Against Epilepsy (ILAE) Executive Committee for Epilepsia. William D. Gaillard and Adam L. Hartman serve on the Editorial Board for Epilepsia. The remaining authors have no conflicts of interest. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.